Engineered Extracellular Vesicles for KRAS Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering antisense oligonucleotides (ASOs) to reduce KRAS protein expression in cells are limited by stability and targeting efficiency, necessitating the development of more effective engineered extracellular vesicles (EVs) for therapeutic applications, particularly in cancer treatment.
Innovation Solution
The development of EVs, such as exosomes, loaded with antisense oligonucleotides (ASOs) that are complementary to KRAS G12D transcripts, which can specifically target and reduce KRAS protein expression in human cells by up to 100%, utilizing scaffold proteins and targeting moieties for enhanced delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug delivery methods are used to deliver antisense oligonucleotides, then the delivery process is simple, but the stability and targeting efficiency are insufficient
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as intermediary carriers to deliver antisense oligonucleotides. The EVs naturally protect the ASOs from degradation and provide targeted delivery to specific cells, thereby improving stability and targeting efficiency without requiring complex synthetic delivery systems
Solution Approach 2:
The patent exploits the natural properties of extracellular vesicles to perform delivery functions. The EVs self-assemble, self-protect the cargo, and self-target to specific cells through endogenous mechanisms, eliminating the need for complex external delivery infrastructure
2Manufacturing precision
If extracellular vesicles with scaffold proteins and targeting moieties are used, then targeting capabilities are enhanced, but the device complexity increases
Solution Approach 1:
The patent introduces scaffold proteins and targeting moieties at specific locations on the EV surface. This localized modification approach enhances targeting precision to specific cells while maintaining the overall simplicity of the EV structure and avoiding uniform complexification throughout the entire system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered EVs effectively reduce KRAS protein expression in immune and tumor cells by up to 100%, demonstrating improved stability and targeting capabilities compared to traditional delivery methods, with potential for cancer treatment and other therapeutic applications.
Implementation Method 1
antisense oligonucleotides (ASOs) that are complementary to KRAS G12D transcripts
Data Source
AI summary
The present disclosure relates to modified extracellular vesicles, e.g., exosomes, comprising an antisense oligonucleotide (ASO), which is capable of reducing and/or inhibiting expression of KRAS mRNA and/or KRAS protein. ASOs that can be used with the modified extracellular vesicles are also disclosed. Also provided herein are methods for using the exosomes and ASOs to treat and/or prevent diseases, such as cancer.